Gao Z, Li Z, Baker S P, Lasley R D, Meyer S, Elzein E, Palle V, Zablocki J A, Blackburn B, Belardinelli L
Department of Pharmacological Sciences, CV Therapeutics, Palo Alto, California 94304, USA.
J Pharmacol Exp Ther. 2001 Jul;298(1):209-18.
Several potent and selective A2A adenosine receptor agonists are currently available. These compounds have a high affinity for the A2A receptor and a long duration of action. However, in situations where a short duration of action is desired, currently available A2A receptor agonists are less than ideal. From a series of recently synthesized A2A receptor agonists, two agonists (CVT-3146 and CVT-3033) with low affinity were selected for further characterization as selective and short-acting coronary vasodilators. Both compounds were selective for the A2A adenosine receptor (AdoR) versus the A1, A2B, and A3AdoR in binding and functional studies. CVT-3146 and CVT-3033 appeared to be weak partial agonists to cause cAMP accumulation in PC12 cells, but were full and potent agonists to cause coronary vasodilation, a response that has a very large A2A receptor reserve. However, the durations of action of CVT-3146 and CVT-3033 were remarkably shorter than those of the high-affinity agonists CGS21680 or WRC0470, presumably due to the relative lower affinity of CVT-3146 and CVT-3033 for the A2A receptor. Indeed, an inverse relationship was found between the affinity of the various agonists for the A2A receptor and the duration of their actions. These data indicate that low-affinity agonists can produce a response that is of equivalent magnitude but more rapid in termination than that caused by a high-affinity agonist. Hence, the low-affinity A2A agonists CVT-3146 and CVT-3033 may prove to be superior to currently available high-affinity agonists as coronary vasodilators during myocardial imaging with radionuclide agents.
目前有几种强效且选择性的A2A腺苷受体激动剂。这些化合物对A2A受体具有高亲和力且作用持续时间长。然而,在需要短作用持续时间的情况下,目前可用的A2A受体激动剂并不理想。从一系列最近合成的A2A受体激动剂中,选择了两种低亲和力的激动剂(CVT - 3146和CVT - 3033)作为选择性和短效冠状动脉血管扩张剂进行进一步表征。在结合和功能研究中,这两种化合物对A2A腺苷受体(AdoR)相对于A1、A2B和A3AdoR具有选择性。CVT - 3146和CVT - 3033似乎是弱部分激动剂,可导致PC12细胞中cAMP积累,但却是完全且强效的激动剂,可引起冠状动脉血管扩张,这种反应具有非常大的A2A受体储备。然而,CVT - 3146和CVT - 3033的作用持续时间明显短于高亲和力激动剂CGS21680或WRC0470,这可能是由于CVT - 3146和CVT - 3033对A2A受体的亲和力相对较低。实际上,发现各种激动剂对A2A受体的亲和力与其作用持续时间之间存在反比关系。这些数据表明,低亲和力激动剂可产生与高亲和力激动剂引起的反应幅度相当但终止更快的反应。因此,在使用放射性核素剂进行心肌成像期间,低亲和力A2A激动剂CVT - 3146和CVT - 3033作为冠状动脉血管扩张剂可能比目前可用的高亲和力激动剂更具优势。